A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer

Clinical Cancer Research

Volumn 10, Issue 22, 2004, Pages 7450-7456

  Van Ummersen, Lynn ^a   Binger, Kim ^a   Volkman, Jennifer ^a   Marnocha, Rebecca ^a   Tutsch, Kendra ^a   Kolesar, Jill ^a   Arzoomanian, Rhoda ^a   Alberti, Dona ^a   Wilding, George ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LOPERAMIDE; MILTEFOSINE; NSC 639966; PERIFOSINE; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; ESOPHAGUS CANCER; FATIGUE; FEMALE; FOOT PAIN; GALLBLADDER CANCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; KIDNEY CARCINOMA; LEG PAIN; LIVER DYSFUNCTION; LUNG CANCER; MAINTENANCE DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MYALGIA; NAUSEA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; SIGNAL TRANSDUCTION; TONSIL CANCER; UTERINE CERVIX CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEIOMYOSARCOMA; LOPERAMIDE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MODELS, CHEMICAL; NEOPLASMS; PHOSPHORYLCHOLINE; RECEPTORS, SEROTONIN, 5-HT3; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 9344270514     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0406     Document Type: Article

References (10)

1. Hilgard P, Klenner T, Stekar J, Unger C. Alkylphosphocholines: a new class of membrane-active anticancer agents. Cancer Chemother Pharmacol 1993;32(2):90-5.
2. Hilgard P, Klenner T, Stekar J, Nossner G, Kutscher B, Engel J. D-21266, a new heterocyclic alklyphospholipid with antitumor activity. Eur J Cancer 1997;33(3):442-6.
3. Stekar J, Hilgard P, Klenner T, Nossner G, Schumacher W. A second generation of alkylphospholipids with high antineoplastic activity. Proc Am Assoc Cancer Res 1993;34:335.
4. Stekar J, Hilgard P, Voegeli R, et al. Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133. Cancer Chemother Pharmacol 1993;32(6);437-44.
5. Hilgard P, Stekar J, Klenner T, Nossner B, Kutscher B, Engel J. Heterocyclic alkylphospholipids with an improved therapeutic range. Adv Exp Med Biol 1996;416:157-64.
6. Crul M, Rosing H, de Klerk GJ, et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002;38(12):1615-21.
7. Woo EW, Messmann R, Sausville EA, Figg WD. Quantitative determination of perifoxine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2001;759(2):247-57.
8. Kondapaka SB, Singh SS, Dasmahapaxra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2(11):1093-1103.
9. Patel V, Lahusen T, Sy T, Sausville EA, Gutkind JS, Senderowicz AM. Perifosine, a novel alkyphospholipid, induces p21 (WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res 2002;62(5):1401-9.
10. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 2003;14(2):167-73.